search
Back to results

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

Primary Purpose

Adenocarcinoma of the Pancreas, Adenocarcinoma of the Stomach, BRCA1 Mutation Carrier

Status
Terminated
Phase
Phase 1
Locations
United States
Study Type
Interventional
Intervention
veliparib
capecitabine
oxaliplatin
pharmacological study
laboratory biomarker analysis
Sponsored by
National Cancer Institute (NCI)
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Adenocarcinoma of the Pancreas

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Histologically or cytologically confirmed solid tumors that fulfill ≥ 1 of the following criteria:

    • BRCA1/2 mutation and a BRCA-related malignancy

      • Patients without a known BRCA mutation must have a probability of harboring a BRCA gene mutation as assessed by BRCAPRO computer program
      • Patients with a probability of having genetic mutation ≥ 20% or a BRCA mutation based on a non-Myriad test, must have a formal BRCA testing by Myriad Genetic Laboratories
      • Patients with known deleterious BRCA 1 or 2 mutation or a mutation of uncertain significance
      • Patients who refuse BRCA testing not allowed unless they have another acceptable histology
    • First- or second-line metastatic colorectal cancer
    • Any-line metastatic mucinous ovarian cancer
    • Any line of other metastatic gastrointestinal malignancies in which oxaliplatin has shown some activity (i.e., gastric or pancreatic adenocarcinoma)
  • Patients with uncontrolled CNS metastasis are not eligible; patients with CNS metastases who have had them treated and are stable for > 3 months will be eligible; patients must be off steroid treatment prior to study enrollment
  • Measurable disease

    • Patients with ovarian cancer who have a pre-treatment CA 125 level of at least twice the upper limit of normal allowed
  • ECOG performance status (PS) 0-2 (Karnofsky 60-100%)
  • Life expectancy > 3 months
  • ANC ≥ 1,500/mm³
  • Platelet count ≥ 100,000/mm³
  • Total bilirubin ≤ 1.5 times upper limit of normal (ULN)
  • AST and ALT ≤ 2.5 times ULN (≤ 5 times ULN for patients with liver metastases)
  • Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 60 mL/min
  • Fertile patients must use adequate contraception (i.e., hormonal, barrier method of birth control, or abstinence)
  • Not pregnant or nursing
  • Negative pregnancy test
  • No history of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib or other agents used in study
  • No uncontrolled intercurrent illness including, but not limited to, any of the following:

    • Ongoing or active infection
    • Symptomatic congestive heart failure
    • Unstable angina pectoris
    • Cardiac arrhythmia
    • Psychiatric illness and/or social situations that would limit compliance with study requirements
  • No history of positive serology for hepatitis A, B, or C, liver disease, or other forms of hepatitis or cirrhosis
  • Patients who have active seizures or history of seizures are ineligible
  • No condition that impairs the ability to swallow and retain veliparib capsules, including any of the following:

    • Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation
    • Prior surgical procedures affecting absorption
    • Active peptic ulcer disease
  • No malabsorption syndrome, disease significantly affecting gastrointestinal function, resection of the stomach or small bowel, ulcerative colitis, inflammatory bowel disease, or a partial or complete small bowel obstruction
  • No peripheral neuropathy ≥ grade 2
  • No prolonged QTC > 450 msec (male) or QTC > 470 (female)
  • No concurrent combination antiretroviral therapy for HIV-positive patients
  • Recovered from adverse events of prior therapy or prior surgical procedures

    • Patients with chronic grade 1 or 2 adverse events that are not expected to improve are allowed at investigator's discretion
  • At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C)
  • At least 4 weeks since prior radiotherapy with no > 35% of marrow irradiation
  • Prior fluoropyrimidine allowed
  • Prior veliparib allowed provided it was part of a single- or limited-dosing study, such as a phase 0 study
  • Prior capecitabine allowed provided patient tolerated 3500 mg/m² for 7 days out of 14 days
  • No other prior investigational agents
  • No prior oxaliplatin

Sites / Locations

  • University of Wisconsin Hospital and Clinics

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Treatment (veliparib, capecitabine, oxaliplatin)

Arm Description

Patients receive veliparib PO twice daily and capecitabine PO twice daily on 1-7 and 15-21, and oxaliplatin IV over 2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Outcomes

Primary Outcome Measures

Maximum-tolerated (MTD) dose of veliparib in combination with oxaliplatin and capecitabine as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
MTD defined as the dose level at which less than one-third of patients experience a dose-limiting toxicity (DLT).
Dose-limiting toxicities of veliparib in combination with oxaliplatin and capecitabine as assessed by NCI CTCAE version 4.0

Secondary Outcome Measures

Pharmacokinetics of veliparib administered concomitantly with oxaliplatin and capecitabine
Graphical displays of individual, mean, and median plasma concentration over time will be presented at each ABT-888 dose level and overall in the entire group. Descriptive summaries for each pharmacokinetic endpoint will be presented by ABT-888 dose level.
Safety and tolerability as assessed by NCI CTCAE version 4.0
Reported in tabular format, both per dose level, as well as in the aggregate cohort.
Anti-tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST)
Anti-tumor responses will be summarized using descriptive statistics and will be presented in tables. In addition, two-sided 90% confidence intervals for the proportions of subjects with a confirmed anti-tumor response will be obtained.

Full Information

First Posted
November 2, 2010
Last Updated
April 1, 2014
Sponsor
National Cancer Institute (NCI)
search

1. Study Identification

Unique Protocol Identification Number
NCT01233505
Brief Title
Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors
Official Title
A Phase I Study of ABT-888 in Combination With Oxaliplatin and Capecitabine in Advanced Solid Tumors
Study Type
Interventional

2. Study Status

Record Verification Date
October 2013
Overall Recruitment Status
Terminated
Study Start Date
October 2010 (undefined)
Primary Completion Date
October 2013 (Actual)
Study Completion Date
undefined (undefined)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
National Cancer Institute (NCI)

4. Oversight

5. Study Description

Brief Summary
This phase I trial is studying the side effects and the best dose of veliparib when given together with capecitabine and oxaliplatin in treating patients with advanced solid tumors. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as capecitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving veliparib together with capecitabine and oxaliplatin may kill more tumor cells.
Detailed Description
PRIMARY OBJECTIVES: I. To determine the dose limiting toxicities (DLTs) and the maximum tolerated dose (MTD) of ABT-888 (veliparib) in combination with oxaliplatin and capecitabine in advanced solid tumors. SECONDARY OBJECTIVES: I. To evaluate the pharmacokinetics of ABT-888, oxaliplatin, and capecitabine when administered concomitantly. II. To evaluate the safety and tolerability of the ABT-888 in combination with capecitabine and oxaliplatin. III. To assess for evidence of anti-tumor activity with this combination, per tumor measurements using RECIST criteria, in these patients. TERTIARY OBJECTIVES: I. To assess the inhibition of poly(ADP-ribose) polymerase (PARP) in peripheral blood mononuclear cells secondary to treatment with ABT-888. II. To determine the pharmacokinetics of ABT-888 in combination with oxaliplatin and capecitabine and the relation to treatment side effects. OUTLINE: This is a dose-escalation study of veliparib. Patients receive veliparib orally (PO) twice daily and capecitabine PO twice daily on 1-7 and 15-21, and oxaliplatin intravenously (IV) over 2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients undergo blood and urine sample collection at baseline and periodically during study for pharmacokinetic and poly (ADP-ribose) polymerase (PARP) inhibition studies. After completion of study therapy, patients are followed up for 30 days.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Adenocarcinoma of the Pancreas, Adenocarcinoma of the Stomach, BRCA1 Mutation Carrier, BRCA2 Mutation Carrier, Ovarian Mucinous Cystadenocarcinoma, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Gastric Cancer, Recurrent Ovarian Epithelial Cancer, Recurrent Ovarian Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Ovarian Epithelial Cancer, Stage IV Ovarian Germ Cell Tumor, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Unspecified Adult Solid Tumor, Protocol Specific

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
16 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Treatment (veliparib, capecitabine, oxaliplatin)
Arm Type
Experimental
Arm Description
Patients receive veliparib PO twice daily and capecitabine PO twice daily on 1-7 and 15-21, and oxaliplatin IV over 2 hours on days 1 and 15. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.
Intervention Type
Drug
Intervention Name(s)
veliparib
Other Intervention Name(s)
ABT-888
Intervention Description
Given PO
Intervention Type
Drug
Intervention Name(s)
capecitabine
Other Intervention Name(s)
CAPE, Ro 09-1978/000, Xeloda
Intervention Description
Given PO
Intervention Type
Drug
Intervention Name(s)
oxaliplatin
Other Intervention Name(s)
1-OHP, Dacotin, Dacplat, Eloxatin, L-OHP
Intervention Description
Given IV
Intervention Type
Other
Intervention Name(s)
pharmacological study
Other Intervention Name(s)
pharmacological studies
Intervention Description
Correlative studies
Intervention Type
Other
Intervention Name(s)
laboratory biomarker analysis
Intervention Description
Correlative studies
Primary Outcome Measure Information:
Title
Maximum-tolerated (MTD) dose of veliparib in combination with oxaliplatin and capecitabine as assessed by the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.0
Description
MTD defined as the dose level at which less than one-third of patients experience a dose-limiting toxicity (DLT).
Time Frame
28 days
Title
Dose-limiting toxicities of veliparib in combination with oxaliplatin and capecitabine as assessed by NCI CTCAE version 4.0
Time Frame
28 days
Secondary Outcome Measure Information:
Title
Pharmacokinetics of veliparib administered concomitantly with oxaliplatin and capecitabine
Description
Graphical displays of individual, mean, and median plasma concentration over time will be presented at each ABT-888 dose level and overall in the entire group. Descriptive summaries for each pharmacokinetic endpoint will be presented by ABT-888 dose level.
Time Frame
At baseline, at 0.5, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 12, and 24 hours of days 1 and 7
Title
Safety and tolerability as assessed by NCI CTCAE version 4.0
Description
Reported in tabular format, both per dose level, as well as in the aggregate cohort.
Time Frame
Up to 30 days
Title
Anti-tumor response according to Response Evaluation Criteria in Solid Tumors (RECIST)
Description
Anti-tumor responses will be summarized using descriptive statistics and will be presented in tables. In addition, two-sided 90% confidence intervals for the proportions of subjects with a confirmed anti-tumor response will be obtained.
Time Frame
Up to 30 days

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Histologically or cytologically confirmed solid tumors that fulfill ≥ 1 of the following criteria: BRCA1/2 mutation and a BRCA-related malignancy Patients without a known BRCA mutation must have a probability of harboring a BRCA gene mutation as assessed by BRCAPRO computer program Patients with a probability of having genetic mutation ≥ 20% or a BRCA mutation based on a non-Myriad test, must have a formal BRCA testing by Myriad Genetic Laboratories Patients with known deleterious BRCA 1 or 2 mutation or a mutation of uncertain significance Patients who refuse BRCA testing not allowed unless they have another acceptable histology First- or second-line metastatic colorectal cancer Any-line metastatic mucinous ovarian cancer Any line of other metastatic gastrointestinal malignancies in which oxaliplatin has shown some activity (i.e., gastric or pancreatic adenocarcinoma) Patients with uncontrolled CNS metastasis are not eligible; patients with CNS metastases who have had them treated and are stable for > 3 months will be eligible; patients must be off steroid treatment prior to study enrollment Measurable disease Patients with ovarian cancer who have a pre-treatment CA 125 level of at least twice the upper limit of normal allowed ECOG performance status (PS) 0-2 (Karnofsky 60-100%) Life expectancy > 3 months ANC ≥ 1,500/mm³ Platelet count ≥ 100,000/mm³ Total bilirubin ≤ 1.5 times upper limit of normal (ULN) AST and ALT ≤ 2.5 times ULN (≤ 5 times ULN for patients with liver metastases) Creatinine ≤ 1.5 times ULN OR creatinine clearance ≥ 60 mL/min Fertile patients must use adequate contraception (i.e., hormonal, barrier method of birth control, or abstinence) Not pregnant or nursing Negative pregnancy test No history of allergic reactions attributed to compounds of similar chemical or biologic composition to veliparib or other agents used in study No uncontrolled intercurrent illness including, but not limited to, any of the following: Ongoing or active infection Symptomatic congestive heart failure Unstable angina pectoris Cardiac arrhythmia Psychiatric illness and/or social situations that would limit compliance with study requirements No history of positive serology for hepatitis A, B, or C, liver disease, or other forms of hepatitis or cirrhosis Patients who have active seizures or history of seizures are ineligible No condition that impairs the ability to swallow and retain veliparib capsules, including any of the following: Gastrointestinal tract disease resulting in an inability to take oral medication or a requirement for IV alimentation Prior surgical procedures affecting absorption Active peptic ulcer disease No malabsorption syndrome, disease significantly affecting gastrointestinal function, resection of the stomach or small bowel, ulcerative colitis, inflammatory bowel disease, or a partial or complete small bowel obstruction No peripheral neuropathy ≥ grade 2 No prolonged QTC > 450 msec (male) or QTC > 470 (female) No concurrent combination antiretroviral therapy for HIV-positive patients Recovered from adverse events of prior therapy or prior surgical procedures Patients with chronic grade 1 or 2 adverse events that are not expected to improve are allowed at investigator's discretion At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas or mitomycin C) At least 4 weeks since prior radiotherapy with no > 35% of marrow irradiation Prior fluoropyrimidine allowed Prior veliparib allowed provided it was part of a single- or limited-dosing study, such as a phase 0 study Prior capecitabine allowed provided patient tolerated 3500 mg/m² for 7 days out of 14 days No other prior investigational agents No prior oxaliplatin
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
William Schelman
Organizational Affiliation
University of Wisconsin, Madison
Official's Role
Principal Investigator
Facility Information:
Facility Name
University of Wisconsin Hospital and Clinics
City
Madison
State/Province
Wisconsin
ZIP/Postal Code
53792
Country
United States

12. IPD Sharing Statement

Learn more about this trial

Veliparib, Oxaliplatin, and Capecitabine in Treating Patients With Advanced Solid Tumors

We'll reach out to this number within 24 hrs